• Home
  • Search Results
  • Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy.

Identification of fluocinolone acetonide to prevent paclitaxel-induced peripheral neuropathy.

Journal of the peripheral nervous system : JPNS (2016-04-28)
Aysel Cetinkaya-Fisgin, Min Geol Joo, Xiang Ping, Nitish V Thakor, Cengizhan Ozturk, Ahmet Hoke, In Hong Yang
ABSTRACT

Paclitaxel (PTX) is among the most commonly used cancer drugs that cause chemotherapy-induced peripheral neuropathy (CIPN), a debilitating and serious dose-limiting side effect. Currently, no drugs exist to prevent CIPN, and symptomatic therapy is often ineffective. In order to identify therapeutic candidates to prevent axonal degeneration induced by PTX, we carried out a phenotypic drug screening using primary rodent dorsal root ganglion sensory neurons. We identified fluocinolone acetonide as a neuroprotective compound and verified it through secondary screens. Furthermore, we showed its efficacy in a mouse model of PTX-induced peripheral neuropathy and confirmed with four different cancer cell lines that fluocinolone acetonide does not interfere with PTX's antitumor activity. Our study identifies fluocinolone acetonide as a potential therapy to prevent CIPN caused by PTX.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Insulin solution from bovine pancreas, 10 mg/mL insulin in 25  mM HEPES, pH 8.2, BioReagent, sterile-filtered, suitable for cell culture